Driver Mutations in Cancer: Oncogenes, Tumor Suppressors, and Therapeutic Targeting

Driver mutations confer selective growth advantage to cancer cells; they are causally implicated in oncogenesis. Distinct from passenger mutations (neutral, accumulate randomly).

Two Major Classes

ClassNormal FunctionMutation EffectExamples
OncogenesPromote proliferation, survival, growth (proto-oncogenes)Gain-of-function (activating): overexpression, constitutive activationEGFR, HER2, KRAS, BRAF, MYC, BCR-ABL, ALK
Tumor Suppressor Genes (TSGs)Inhibit proliferation, promote apoptosis, repair DNA, control cell cycleLoss-of-function (inactivating): deletions, truncations, epigenetic silencingTP53, RB1, PTEN, APC, VHL, NF1

Origin

  • Somatic (acquired): >90% of drivers; arise during life (environmental mutagens, replication errors, APOBEC).
  • Germline (inherited): Predisposition syndromes (e.g., BRCA1/2, TP53 Li-Fraumeni, APC FAP). Present in all cells.

Key Pathways Frequently Altered

  • RTK/RAS/PI3K (growth/survival)
  • p53/DNA damage response
  • Cell cycle (RB, CDK4/6, cyclins)
  • Wnt/β-catenin
  • TGF-β
  • Chromatin remodeling (SWI/SNF, histone modifiers)

Therapeutic Implications

  • Targeted therapies: Inhibit oncogenic drivers (e.g., imatinib for BCR-ABL, osimertinib for EGFR, vemurafenib for BRAF V600E).
  • Synthetic lethality: PARP inhibitors in BRCA-mutant cancers.
  • Resistance: Secondary mutations, bypass tracks, phenotypic plasticity.
  • Biomarker-driven trials: Basket trials (mutation-based, not tissue-based).

Identifying driver mutations via NGS (next-gen sequencing) is now standard in advanced cancers to guide precision oncology.

Genetic Disorders - Related Articles